News
May 11, 2026
Inhalon Biopharma to Present Inhaled Antibody Platform for Acute Respiratory Infections at ATS 2026 Respiratory Innovation Summit Read More
May 8, 2026
Inhalon Biopharma to Present Poster on IN‑007 at RDD 2026 Read More
February 19, 2026
Inhalon Biopharma Presented an Update on IN-002, an Inhaled Antibody Treatment for RSV, at RSVVW 2026 Read More
February 26, 2025
Inhalon Biopharma Announces Publication of Phase 1 Clinical Trial Data for IN-006, Its Inhaled Antibody Treatment for COVID-19 Read More
February 10, 2025
Inhalon Biopharma to Share Progress in Advancing Inhaled Antibody Therapy Platform for Treating Respiratory Infections at BIO CEO & Investor Conference Read More
August 26, 2024
Inhalon Biopharma Announces Poster Presentation at Military Health System Research Symposium 2024 Read More
June 3, 2024
Inhalon Biopharma to Provide Update on Inhaled Monoclonal Antibody Therapy Platform at BIO International Convention Read More
April 25, 2024
Inhalon Biopharma to Share Progress on Inhaled Monoclonal Antibody Therapy at 9th Annual Inhalation and Respiratory Drug Delivery Congress Read More
March 20, 2024
Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing Read More
March 14, 2024
Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections Read More
January 8, 2024
Inhalon Biopharma to Present on Product Development Pipeline at Biotech Showcase Read More
November 15, 2023
Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19 Read More
November 1, 2023
Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia Read More
October 6, 2023
Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe Read More
June 30, 2022
Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies Read More
October 7, 2021
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19 Read More
July 22, 2021
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home Read More
July 16, 2021
Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer Read More
May 26, 2021
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19 Read More